BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250312T080000
DTEND;TZID=America/New_York:20260312T170000
DTSTAMP:20260421T081317
CREATED:20250620T061332Z
LAST-MODIFIED:20250620T062541Z
UID:10000002-1741766400-1773334800@mednetus.net
SUMMARY:Ocular Surface Disease: Pathophysiology\, Evaluation\, Management with Topical Agents\, and Neuromodulation
DESCRIPTION:CME | 1.25 Credits \n\n\n\n\n\n\nWebcast \nTime to Complete: 75 minutes \nReleased: March 12\, 2025 \nExpires: March 12\, 2026 \nMaximum Credits:\n1.25 / AMA PRA Category 1 CreditsTM \n\n\n\n\n\n\n\n\n\nStart Activity\n\n\n\nProgram Description \nThis webcast provides an update on the ocular surface diseases. Cornea and conjunctiva\, lids\, exocrine glands and their innervation form an integrated entity\, which regulates the production of tear fluid.1 Stable tear fluid is essential in nourishing and protecting the ocular surface from external threats\, such as pollution\, desiccation\, injuries\, allergens and pathogens. Maintaining and protecting the transparent\, avascular cornea is particularly important for good visual acuity. Thus\, an integral part of the functioning of the ocular surface relies on the tear fluid. \nIntended Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surfaces diseases. \nCommercial Supporter \nThis activity is supported by an educational grant from Dompé US Inc. \n\n\n\n\n\n\n\n\nLearning Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nSummarize the pathophysiology\, risk factor\, and evaluation of ocular surface disease\nInterpret data on artificial tear formulations and neuromodulation in managing ocular surface disease\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAccredited Providers \nThis activity is provided by Amedco and MedNet. \n       \nJoint Accreditation Statement \nIn support of improving patient care\, Amedco and MedNet have planned and implemented this activity. Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. MedNet serves as the content and logistic provider for this activity. Amedco designates this activity for 1.25 AMA PRA Category 1 CreditsTM \nPhysicians Credit Designation \nAmedco designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nAdditional Credit Information \nPhysician Assistants\nAAPA accepts AMA PRA Category 1 CreditTM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors\, and allows reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours. \nThrough an agreement between the American Medical Association (AMA) and the European Union of Medical Specialists\, physicians and healthcare providers may convert CME/CE PRA Category 1 CreditsTM to an equivalent number of European CME Credits® (ECMECs®). The UEMS-EACCME® has recognition agreements with the AMA for live events and e-learning materials. \nFaculty \n \nSarah B. Sunshine\, MD\nAssistant Professor\, Ophthalmology\nUniversity of Maryland and Greenebaum Comprehensive Cancer\nBaltimore\, MD \nDr. Sunshine discloses the following:\nConsultant: Astra Zeneca\, GSK\nResearch Support: Incyte (IIT)\, Eversight\, NIH \n\nInstructions \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nACCME – Amedco\nPhone Number: 651-789-3730\nE-Mail: Sheryl@amedcoemail.com \nPrivacy Policy \nmyCME privacy policy
URL:https://mednetus.net/event/ocular-surface-disease-pathophysiology-evaluation-management-with-topical-agents-and-neuromodulation/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/032rt0jpt6u4-OSD800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250412T080000
DTEND;TZID=America/New_York:20250412T170000
DTSTAMP:20260421T081317
CREATED:20250620T061036Z
LAST-MODIFIED:20250620T070003Z
UID:10000001-1744444800-1744477200@mednetus.net
SUMMARY:Dry Eye Disease: Current and Emerging Novel Tear Stimulating Therapies for Improved Outcomes
DESCRIPTION:Take Me to the Event Registration\n\n\n\nEVENT Summary \nDates \nSaturday\, April 12\, 2025\, 10:00 AM ET\, 9:00 AM CT\, 8:00 AM MT\, and 7:00 AM PT \nLocation \nVirtual \nTarget Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with dry eye disease (DED) \nFormat \nZoom Webinar \nCredits \n1.25 / AMA PRA Category 1 Credit(s)TM\n1.25 / COPE CE Credits \nCost \nFree \n\nProgram Description \nClick to Go to the Event Registration \nThis program will provide up-to-date\, evidence-based information on DED\, evaluations\, and emerging therapies. The activity will focus on: \nPathophysiology of DED – The pathogenesis of MGD and DED can be described as a ‘vicious circle’; the underlying pathophysiological mechanisms of DED and MGD interact\, resulting in a ‘double vicious circle’ \n\nThe vicious circle of DED\nDual “Vicious Circle” of DED and MGD\nFactors Contributing to DED\n\nPreservatives in topicals contribute to DED\nDED in patients after refractive or cataract surgery\nDED in postmenopausal women\nDED in patients with autoimmune disorders\n\n\n\nAvailable Treatment Options for MGD-Associated DED – Treatment for MGD-associated DED encompasses a wide range of approaches\, such as: \n\nPreservative-free Artificial Tears\,\nWarming and Eyelid Compression\,\nThermal Pulsation\,\nLipiFlow Thermal Pulsation System\,\nIntense Pulsed Light (IPL) Therapy\,\nTopical and oral Azithromycin\,\nIntraductal probing\,\nHormone Replacement Therapy (HRT) to alleviate DED in menopausal women\,\nTopical anti-inflammatory therapies\, such as tacrolimus and cyclosporin A for DED in patients with autoimmune diseases\n\nNovel Tear Stimulating Therapies \nNew treatment options for DED – Several pharmacologic agents with novel mechanisms of action for treating DED are under development. \n\nVarenicline nasal spray\nPerfluorohexyloctane ophthalmic solution (Miebo®)\nLifitegrast\nReproxalap\nWater-free topical cyclosporine\, 0.1% and 0.5%\nAZR-MD-001 (selenium sulfide ophthalmic ointment)\nNOV03 (perfluorohexyloctane)\nLotilaner (TP-03)\n\nAgenda \n• Discuss the pathophysiology and factors contributing to DED such as preservatives in topicals\, refractive or cataract surgery\, menopause\, and autoimmune diseases – Neal Guymon\, OD \n• Discuss the real-world evidence surrounding available and new tear-stimulating therapies to improve patient outcomes of individuals with DED – Eric D. Donnenfeld\, MD \nIntended Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with dry eye disease (DED). \nCommercial Supporter \nSupported by an unrestricted educational grant from Oyster Point \nLearning Objectives \n\nSummarize the pathophysiology and factors contributing to DED\, such as preservatives in topicals\, refractive or cataract surgery\, menopause\, and autoimmune diseases\nAssess real-world evidence surrounding available and new tear-stimulating therapies to improve patient outcomes of individuals with DED\n\nAccredited Providers \nAmedco and MedNet have collaborated to design and execute this activity. \n       \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. \nPhysicians (ACCME) Credit Designation \nAmedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nOptometrists Credit \nThis activity\, COPE course 97133-TD\, is accredited by COPE for continuing education for optometrists. COPE Activity ID#130386. \nMedNet designates this activity for a maximum of 1.25 COPE credits. \nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nPlanners’ and Managers’ Disclosures \nAll relevant relationships have been reviewed and mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \nFaculty \n \nNeal Guymon\, OD\nOptometrist\nSummit EyeCare\nIdaho Falls\, ID \n \nEric D. Donnefeld\, MD\nClinical Professor of Ophthalmology\nNew York University Langone Medical Center\nOphthalmic Consultants of Long Island\nNew York\, NY \nInstructions/Technical Requirements \nHardware: An internet-enabled computer\, smartphone\, tablet\, or other mobile device with audio and internet capabilities. \nSoftware: Installation of software like Zoom may be necessary. \nCost \nThere are no fees for participating and receiving CME and COPE credit for this activity. \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/dry-eye-disease-current-and-emerging-novel-tear-stimulating-therapies-for-improved-outcomes/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/cgnwskl7e5i1-800x450-1.jpg
END:VEVENT
END:VCALENDAR